secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001193125-24-070706
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics paltusotine meets all endpoints in Phase 3 acromegaly study; NDA planned 2H 2024
--------------------------------------------------------------------------------

- Primary endpoint: 56% of paltusotine patients achieved IGF-1 ≤1.0 xULN vs 5% placebo (p<0.0001).
- All secondary endpoints met: IGF-1 change, GH <1.0 ng/mL, and Acromegaly Symptoms Diary score.
- No serious adverse events reported; common TEAEs included diarrhea, headache, arthralgia, abdominal pain.
- Crinetics to submit NDA to FDA in 2H 2024; potential launch in 2025.
- PATHFNDR-2 enrolled 111 untreated acromegaly patients in a 24-week placebo-controlled trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524070706/0001193125-24-070706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524070706/d814079d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-070706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer